Reply to Trudeau, M.; Fraser, B. The CADTH pCODR Expert Review Committee Process Explained. Comment on "Rayson et al. Access to Neoadjuvant Pertuzumab for HER2 Positive Breast Cancer in Canada: A Dilemma Increasingly Difficult to Explain.
Journal
Current oncology (Toronto, Ont.)
ISSN: 1718-7729
Titre abrégé: Curr Oncol
Pays: Switzerland
ID NLM: 9502503
Informations de publication
Date de publication:
16 05 2023
16 05 2023
Historique:
received:
15
03
2023
accepted:
09
05
2023
medline:
29
5
2023
pubmed:
26
5
2023
entrez:
26
5
2023
Statut:
epublish
Résumé
We appreciate the opportunity to respond to the comment [...].
Identifiants
pubmed: 37232839
pii: curroncol30050381
doi: 10.3390/curroncol30050381
pmc: PMC10217302
doi:
Substances chimiques
pertuzumab
K16AIQ8CTM
Trastuzumab
P188ANX8CK
Receptor, ErbB-2
EC 2.7.10.1
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
5050-5053Références
Curr Oncol. 2023 May 16;30(5):5047-5049
pubmed: 37232838
Int J Technol Assess Health Care. 2008 Summer;24(3):244-58; discussion 362-8
pubmed: 18601792
Curr Oncol. 2022 Dec 16;29(12):9891-9895
pubmed: 36547192
Lancet Oncol. 2016 Jun;17(6):791-800
pubmed: 27179402
N Engl J Med. 2019 Feb 14;380(7):617-628
pubmed: 30516102